Clinical‑stage Aspen Neuroscience closed a $115 million Series C to advance ANPD001, its autologous iPSC‑derived cell therapy for Parkinson’s disease, and to scale manufacturing and pipeline programs. Aspen cited Fast Track designation from the FDA, ongoing Phase I/IIa dosing (including a commercial formulation cohort), and safety and six‑month efficacy signals from earlier cohorts as drivers for the raise. The company plans to expand manufacturing capacity, integrate ML and genomics for product characterization, and develop additional autologous iPSC‑derived candidates for other neurological indications.